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ABSTRACT
B-Raf represents a critical physiological regulator of the Ras/RAF/MEK/ERK-
pathway and a pharmacological target of growing clinical relevance, in particular in 
oncology. To understand how B-Raf itself is regulated, we combined mass spectrometry 
with genetic approaches to map its interactome in MCF-10A cells as well as in B-Raf 
deficient murine embryonic fibroblasts (MEFs) and B-Raf/Raf-1 double deficient DT40 
lymphoma cells complemented with wildtype or mutant B-Raf expression vectors. 
Using a multi-protease digestion approach, we identified a novel ubiquitination site 
and provide a detailed B-Raf phospho-map. Importantly, we identify two evolutionary 
conserved phosphorylation clusters around T401 and S419 in the B-Raf hinge region. 
SILAC labelling and genetic/biochemical follow-up revealed that these clusters are 
phosphorylated in the contexts of oncogenic Ras, sorafenib induced Raf dimerization 
and in the background of the V600E mutation. We further show that the vemurafenib 
sensitive phosphorylation of the T401 cluster occurs in trans within a Raf dimer. 
Substitution of the Ser/Thr-residues of this cluster by alanine residues enhances the 
transforming potential of B-Raf, indicating that these phosphorylation sites suppress 
its signaling output. Moreover, several B-Raf phosphorylation sites, including T401 
and S419, are somatically mutated in tumors, further illustrating the importance of 
phosphorylation for the regulation of this kinase.
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INTRODUCTION
The Ras/Raf/mitogen-activated/extracellular-regulated 
kinase (MEK)/extracellular signal regulated kinase (ERK) 
pathway plays a pivotal role in controlling proliferation, 
survival and differentiation of metazoan cells. The Raf tier 
represents a particularly important node as these Ser/Thr-
kinases are subject to a complex, still ill-defined activation 
process that integrates various protein-protein and –lipid 
interactions and positive as well as negative phosphorylation 
events [1-3]. The Raf family comprises the A-Raf, B-Raf 
and Raf-1 (aka C-Raf) isoforms in vertebrates as well as 
D-Raf and LIN-45 in Drosophila and Caenorhabditis, 
respectively. Genetic approaches in mice and chicken DT40 
B cells demonstrated that Raf-1 and B-Raf have unique, but 
also overlapping functions [4-7]. B-Raf, the most potent 
kinase of the family, plays an important role in various 
developmental processes [8]. This is reflected by the various 
germ-line BRAF mutations found in the neuro-cardio-facio-
cutaneous syndromes or RASopathies [9, 10]. Furthermore, 
B-Raf, as the most frequently mutated kinase in cancer, has 
become an important target in clinical oncology, in particular 
in melanoma and hairy cell leukemia, with other diseases 
following suit [2, 11]. The multi-kinase inhibitor sorafenib, 
originally developed to block Raf-1 in tumor cells with 
aberrant Ras signaling [12], also targets B-Raf, although its 
efficacy in B-Raf driven melanoma has been disappointing 
[11]. Nevertheless, sorafenib affects B-Raf signaling 
complexes, in particular Raf dimerization, at concentrations 
achievable in patients treated with this drug for receptor 
tyrosine kinase (RTK) driven tumor entities [13, 14]. Thus, 
we require an in-depth knowledge as to how sorafenib 
interferes with B-Raf, even if this interaction is not pursued 
therapeutically. In contrast, more specific B-Raf inhibitors 
like vemurafenib and dabrafenib yield unprecedented 
response rates in melanoma [11, 15]. However, the use of 
existing Raf-inhibitors is restricted to tumor cells with 
BRAFV600E/K mutations as the binding of these compounds 
to wildtype B-Raf provokes the paradoxical activation of 
the MEK/ERK pathway. This phenomenon, which causes 
therapy resistance and side effects including secondary 
neoplasms, involves the presence of active Ras and hetero-
dimerization between a drug-bound and a drug-free Raf 
protomer [14, 16-19]. Consequently, alternative strategies for 
the inhibition of Raf-kinases in the context of aberrant Ras 
signaling are urgently needed and might emerge from studies 
of basic principles underlying B-Raf regulation.
Our current knowledge of B-Raf regulation is best 
approached from a structural perspective [2]. B-Raf and 
the other Raf isoforms share three conserved regions (CR) 
that display a higher degree of sequence similarity between 
the Raf family members (Figure 4). The CR1 is placed 
C-terminal of the B-Raf specific region (BSR) and contains 
two subdomains, the Ras-binding domain (RBD) and the 
Cysteine-rich domain (CRD) that are both involved in Ras 
binding. The CR2 contains several phosphorylation sites 
of which phosphorylated S365 plays an important role for 
maintaining B-Raf in an auto-inhibited state by serving as 
a 14-3-3 binding site. The CR3 encompasses the N-region 
and the kinase domain and follows the hinge region, a stretch 
of low inter-paralogue sequence homology and diversity 
generated by alternative splicing [20]. The kinase domain also 
contains several residues involved in Raf dimerization with 
R509 in the dimer interface (DIF) playing a key role in this 
process [13, 21]. B-Raf is fully activated by conformational 
changes induced by phosphorylation of the T599VKS602-motif 
in its activation loop, a step mimicked by the most common 
oncogenic BRAF mutation, V600E [22-24]. The C-terminal 
end of the CR3 is marked by a second 14-3-3 binding motif 
around S729 that is crucial for B-Raf activation [25-28] and 
contains negative ERK controlled feedback phosphorylation 
sites in the SPKTP-motif [29, 30].
Although many details are still missing, the 
following model of the B-Raf activation cycle has 
emerged from studies conducted on B-Raf and Raf-1 over 
the last 20 years [31]. In its inactive state, B-Raf is kept 
in a closed auto-inhibited state in which the N-terminal 
moiety comprising the BSR, CR1 and CR2 folds over the 
CR3 and potentially prevents activating phosphorylation 
and protein-protein interaction events, in particular 
dimerization. Experiments using B-Raf proteins with 
mutations in the CRD, e.g. the RASopathy associated 
Q257R substitution, or in the CR2, e.g. S365A, have 
revealed the critical role of CR1/CR2 for auto-inhibition 
[13, 25, 27]. Following its interaction with active Ras-
proteins (Ras-GTP), the N-terminal moiety becomes 
displaced from the CR3 and re-binding of the 14-3-3 
dimer, which clamps the N- and C-terminal moieties 
together, is prevented by de-phosphorylation of S365 
[32]. This more open conformation of B-Raf then might 
trigger a series of post-translational modifications (PTMs), 
in particular phosphorylation events and its homo- and 
hetero-dimerization with Raf-1, A-Raf or the related 
KSR proteins. As hetero-dimers display a distinct MEK 
phosphorylation potential compared to homo-dimers 
[30, 33], the control of the composition and stability of 
B-Raf complexes emerges as important regulatory layer 
to control the signaling output of the Ras/ERK pathway 
[3, 34]. Furthermore, dimerization appears to control 
B-Raf phosphorylation as inhibitors such as sorafenib or 
L779450 not only promote the formation of heterodimers, 
but also induce prominent electrophoretic mobility shifts 
(EMS). Likewise, the kinase-dead B-RafD594A mutant, 
which behaves similarly to drug-bound B-Raf in that sense 
that it provokes paradoxical MEK/ERK phosphorylation 
by binding and transactivating Raf-1, also undergoes 
a dramatic EMS in cells with upregulated Ras activity 
[13, 16]. In both cases, however, the phosphorylation 
sites involved in these processes are unknown, further 
illustrating how little we know about the phosphorylation 
events and protein-protein interaction events guiding 
B-Raf through its activation cycle.
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In this study, we report the detailed analysis of 
reconstituted and endogenous B-Raf complexes in various 
cellular model systems by quantitative and qualitative mass 
spectrometry. We provide a detailed catalog of interaction 
partners and map phosphorylation events induced by 
clinically relevant Raf inhibitors. Functional characterization 
of phosphorylation sites using combinatorial approaches of 
proteomics, biochemistry and genetics reveals molecular 
mechanisms underlying B-Raf regulation.
RESULTS
Generation of model systems for (phospho)
proteomic analyses of B-Raf complexes
To identify core and potentially accessory and cell-
type specific components of B-Raf containing protein 
complexes as well as underlying regulatory mechanisms, 
we decided to analyze the composition of complexes 
and phosphorylation/ubiquitination sites on B-Raf itself 
across various cell lines and under different conditions. 
Therefore, we established four cell line models, allowing 
the highly efficient purification of hemagglutinin-(HA)-
tagged B-Raf proteins. The first model system represents 
a genetic complementation system of B-Raf/Raf-1 double 
deficient DT40 cells [5] that were transfected with a 
retroviral vector encoding HA-tagged chicken B-Raf 
(Figure 1A). As chicken lack Araf, this system provides 
the unique opportunity to study the function and protein-
protein interactions of Raf mutants in vertebrate cells 
without the interference by endogenous Raf-proteins.
Secondly, we used Braf deficient murine embryonic 
fibroblasts (MEFs) expressing a 4-hydroxytamoxifen- 
(4HT) controllable oncogenic H-RasG12V::ERTM fusion 
protein (Figure 1B/1C). In the absence of 4-HT, the 
H-RasG12V::ERTM fusion protein is held in an inactive 
complex organized by Hsp90. Addition of 4-HT induces 
a conformational change of the ER moiety of the fusion 
protein, leading to its release and pathway activation 
[35]. Using this system, we re-introduced and compared 
B-RafWT and B-RafD594A in the absence or presence of 
oncogenic Ras, the former either singly or in combination 
with sorafenib. As a third model system, we purified 
endogenous protein from B-Raf expressing MEFs. In 
both MEF systems, we applied SILAC-based mass 
spectrometry (MS) to obtain quantitative insights into 
protein-protein interactions of B-Raf.
Fourthly, we then used the immortalized human 
mammary epithelial cell line MCF-10A to compare the 
sub-proteomes and PTM spectra between B-RafWT and 
B-RafCAAX, a constitutively activated Raf protein, which 
is tethered to the membrane via the polybasic region 
and CAAX-box of human K-Ras [13]. The pattern of 
co-purified bands and the interactome are quite distinct 
between B-RafWT and B-RafCAAX complexes (Figure 1D).
The use of cell types from different organisms 
expressing HA-tagged B-Raf offers two major advantages: 
Firstly, the two complementation systems (DT40, MEFs) 
provide the unique opportunity to study the function, 
phosphorylation status and protein-protein interactions 
of B-Raf mutants without interference by the endogenous 
protein. Secondly, the complementation with a B-Raf 
cDNA allows the use of small epitope-tags such as 
the hemagglutinin (HA) tag for which highly specific 
antibody resins of high affinity are available. Since 
B-Raf is highly phosphorylated and entertains many 
protein-protein-interactions, antibodies raised against 
the endogenous protein might enrich or discriminate 
against certain subpopulations. Indeed, one commercially 
available antibody displays impaired binding to feedback-
phosphorylated B-Raf [29]. Nevertheless, the approach 
using ectopically expressed epitope-tagged B-Raf 
bears the risk that detected protein-protein interactions 
represent overexpression artifacts. Therefore, we aimed to 
confirm interactions using endogenous B-Raf protein in 
the aforementioned MEF system by MS (Supplementary 
Table S1) or, if suitable antibodies were available, by co-
immunoprecipitation experiments using either tagged or 
endogenous B-Raf.
New insights into the B-Raf interactome and its 
dynamics
Using label-free and SILAC-based quantitative mass 
spectrometry (MS), we aimed to obtain novel insights 
into the composition of B-Raf signalosomes (Figure 2A 
and Supplementary Table S1). Therefore, we performed 
affinity purifications against endogenous or HA-tagged 
versions of B-Raf and compared protein enrichments to 
IgG control IPs, or anti-HA IPs using cells infected with 
the empty vector only, respectively. Interacting proteins 
had to be consistently enriched in two biological replicates 
each (p<0.05 in at least one of the two IPs). As expected, 
we could identify known B-Raf interaction partners such 
as MEK1, MEK2, the 14-3-3 family and the Hsp90/Cdc37 
chaperone complex in all species [36-40]. Chaperones of 
the Hsp70 family and their regulators, the DnaJ/Hsp40 
proteins [41], were also present in B-Raf complexes. 
Likewise, two components of the PP2A phosphatase 
complex, which has been implicated in the recycling of 
feedback-phosphorylated B-Raf [26], were also present. 
We also co-purified PPP1R10, a regulatory subunit of the 
PP1 holo-phosphatase complex from MEFs, which is in 
line with biochemical and genetic data implicating this 
phosphatase in Raf regulation [32].
In addition to this B-Raf core interactome, we 
identified several other interaction partners, which have 
been reported as interaction partners of B-Raf or Raf-1 
previously, further validating our approach. We detected 
peptides derived from the Casein kinase II holoenzyme 
and the peptidyl-prolyl-cis/trans-isomerase Pin1, which 
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Figure 1: Principle and workflow of the model systems for proteomic studies of B-Raf complexes. A. Add-back of 
HA-tagged B-Raf transgenes into conditional B-Raf and Raf-1 double deficient DK37 cells, a clone of DT40 chicken B-lymphocytes 
expressing the MerCreMer recombinase and containing floxed B-Raf and Raf-1 exons (DT40MCM Raf-1flE3/B-RafflE6). Addition of 4-HT 
leads to Cre-recombinase-mediated inactivation of the raf loci and conversion of the DK37- to the DK37+ clone. The resulting B-Raf and 
Raf-1 deficient cell line was subsequently transfected with bicistronic constructs coding for hemagglutinin (HA)-tagged B-Raf and GFP. 
The pAloxPuro construct was cotransfected into the DK37+ cells as selection marker. B. Scheme of the ERTmH-RASG12V system. In the 
absence of 4-HT, the ERTmH-RASG12V fusion protein is sequestered in large heat shock protein complexes shielding the oncogenic Ras 
moiety [35]. Binding of 4-HT to the estrogen receptor (ER) moiety of the fusion protein induces a conformational change and exposure 
of the H-RasV12 moiety, which in turn recruits B-Raf. In this experimental set-up, HA-tagged B-Raf (or mutants thereof) is expressed 
in Braf deficient MEFs and is then purified using anti-HA antibody agarose conjugates. C. Workflow of a typical experiment using the 
MEF complementation system. D. Example of a Coomassie stained SDS-PAGE showing size-separated HA-agarose precipitates from 
MCF-10Atet cells transfected with the empty vector (V), or constructs expressing B-Rafwt (wt) or B-RafCAAX (CAAX).
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Figure 2: The B-Raf interactome and identification of Gα subunits as novel interaction partners. A. Venn diagram showing 
the proteins identified in B-Raf complexes purified from the four different cellular systems (DT40, Braf knock-out MEFs complemented 
with HA-tagged B-Raf (MEF rec.) or MEFs expressing endogenous B-Raf (MEF end.). B. and C. B-Raf interacts with Gα subunits of 
hetero-trimeric G-proteins in an inducible manner in MEFs from conditional Braf deficient mouse embryos expressing the 4-HT regulated 
recombinase Cre-ERT2. Prior to the experiment, the Braf locus was inactivated by 4-HT exposure or kept intact (- 4HT) and the cells were 
expanded for 5 days. Subsequently, the cells were stimulated with the indicated reagents (in B: EGF: 10 nM epidermal growth factor for 
5 min; HRG: 50 ng/ml β-Heregulin for 5 min C: or 10 nM Pasteurella multocida (PMT) toxin for 2 h) or left untreated (n.s.). In C: same 
set-up as in B, except that cells were stimulated with 10 nM PMT for the indicated time points. Following lysis, B-Raf was purified from 
total cellular lysates (TCLs) using anti-B-Raf (H-145) polyclonal antibodies and immunoprecipitates (IPs) were subject to Western blot 
analysis using an antibody raised against the highly conserved switch region common to all Gα subunits (Gα switch). Note the absence of 
Gα subunits in immunoprecipitates (IP) from 4-HT treated MEFs.
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have been implicated in N-region phosphorylation and 
phosphorylation-dependent isomerization of Raf-kinases, 
respectively [26, 42]. In addition to Pin1, another peptidyl-
prolyl-cis/trans-isomerase, the immunophilin FKBP5, 
was found in B-Raf complexes from DT40 and MCF-10A 
cells as it was also recently reported for HEK 293T cells 
[43]. The identification of FKBP5 in B-Raf complexes is 
of particular interest since these proteins inhibit the Ser/
Thr-Phosphatase Calcineurin that in turn has been shown 
to regulate B-Raf activity by dephosphorylating T401 
[44]. We also confirmed the interaction of B-Raf with 
the scaffold protein IQGAP1 in all cell line models and 
identified IQGAP3 as a novel interaction partner in MEFs 
and MCF-10A cells. The critical role of IQGAP1 as an 
important scaffold protein organizing the RAF/MEK/ERK 
pathway and as a potential pharmacological target has 
been recently demonstrated [45]. Likewise, IQGAP3, an 
isoform specifically expressed in proliferating cells, plays 
a critical role in Ras/ERK mediated proliferation [46].
Prohibitin has been implicated in the regulation 
of Raf-1 signaling [47]. Here we show now that this 
protein and the related prohibitin-2 bind to B-Raf as well. 
Likewise, we identified the Raptor subunit of the mTOR 
complex. This represents an interesting finding, as B-Raf 
is associated with mTOR (Frap1) and Rictor in murine T 
cells [48].
Among the novel B-Raf interaction partners we 
identified several α-subunits of hetero-trimeric G-proteins 
(Supplementary Table S1). The observation that Gα 
subunits could be co-purified with B-Raf from distinct 
cellular model systems belonging to three vertebrate 
species suggests that they could reflect a novel signaling 
pathway leading to B-Raf activation. Therefore, we 
confirmed this interaction by co-immunoprecipitation 
of endogenous proteins (Figure 2B/2C). To this end, 
we stimulated B-Raf pro- and deficient MEFs with 
epidermal growth factor (EGF), β-Heregulin (HRG) 
and Pasteurella multocida toxin (PMT). This highly 
mitogenic bacterial toxin promotes the deamidation of 
a glutamine residue essential for GTP hydrolysis in the 
Gα subunits of heterotrimeric G-proteins, which in turn 
abolishes their intrinsic GTPase activity [49]. Thus, PMT 
locks Gα subunits in their GTP-bound state and has a 
similar effect as oncogenic mutations in Gα subunits or 
in Ras-proteins. Treatment of Braf proficient MEFs with 
EGF or HRG promoted the interaction between B-Raf 
and Gα subunits, while stimulation with PMT caused an 
even stronger interaction between B-Raf and Gα subunits 
(Figure 2B/2C). Unfortunately, due to the lack of suitable 
precipitating antibodies, we could not demonstrate the Gα/
B-Raf interaction by reciprocal co-immunoprecipitation. 
Importantly, the Gα subunits were not purified from 
their Braf deficient counterparts, indicating their specific 
interaction with B-Raf and ruling out an unspecific binding 
to IgG or protein G sepharose beads. Taken together, these 
findings confirm Gα subunits as novel components of the 
B-Raf interactome.
Compared to label-free MS, SILAC-based MS 
permits a more precise quantification of known and novel 
interaction events in the B-Raf signalosome (Figure 
3A). For example, SILAC-based MS analysis of B-Raf 
complexes purified from DT40 cells revealed distinct 
degrees of enrichment for MEK1 (MAP2K1) versus 
MEK2 (MAP2K2) and the various 14-3-3 (YWAx) 
isoforms (Figure 3B and Supplementary Table S2). 
Furthermore, this approach identified several proteins 
as regulated interaction partners as their ratio was 
significantly changed in B-Raf complexes from control 
vs. the perturbed sample. For example, sorafenib induced 
the marked increase of B-Raf/Raf-1 and B-Raf/A-
Raf heterodimers in MEFs with active Ras-signaling 
(Figure 3B/3C and Supplementary Table S3), as we had 
described for this experimental system previously [13]. 
Likewise, we observed in the protein complex organized 
by the B-RafD594A mutant significantly higher levels of 
Raf-1 derived peptides than in B-RafWT complexes in 
the context of H-RasG12V::ERTM release (Figure 3B/3C 
and Supplementary Table S4). These SILAC ratios 
are in agreement with our previously published co-
immunoprecipitation/Western blot analyses [13] and with 
the independently reproduced data set in Figure 3C. This 
validates our approach and provides good confidence into 
the SILAC ratios for B-Raf interaction partners that could 
not be confirmed by Western blotting due to the lack of 
suitable antibodies.
Importantly, our SILAC-based experiments also 
revealed dynamically regulated novel interaction partners 
such as the proteasome-associated protein ECM29 homolog, 
which is enriched in MEFs expressing the B-RafD594A 
mutant compared to those complemented with B-RafWT 
(Figure 3B). ECM29 represents an adaptor associated with 
the 26S proteasome and based on the observation that the 
expression level of B-RafD594A mutant often appears reduced 
in cells with oncogenic Ras signaling [13, 16], this finding 
is of particular interest, also in conjunction with the de-
ubiquitinase USP7 found in B-Raf complexes from MEFs 
and DT40 cells. Interestingly, B-RafD594A also associated 
with IQGAP3, Myosin 9b, a unique myosin with Rho-GAP 
activity, and phospholipid metabolizing enzymes such as 
phospholipase D2 and sphingosine-1-phosphate lyase in 
a dynamic fashion (Figure 3B). These interactions might 
reflect the increased membrane residency of drug-bound 
or kinase-dead B-Raf that has been described previously 
[50]. Based on our finding by SILAC-based MS, we also 
confirmed the marked increase in the interaction of B-Raf 
with KidinsS220/ARMS by Western blotting in sorafenib-
treated MEFs with oncogenic Ras signaling (Figure 3D). 
This membrane-spanning docking protein is involved in the 
regulation of ERK signaling in neurons and lymphocytes 
[48, 51].
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Figure 3: SILAC-based MS reveals inducible B-Raf protein complexes. A. Flow-chart for SILAC-based MS experiments. 
B. B-Raf network in three experimental systems. Top: B-Raf interacting proteins were identified in DT40 cells by anti-HA-B-Raf 
IPs compared to vector control cells (n=2; p<0.05). Middle: B-Raf network under sorafenib treatment in MEFs with active H-RasV12 
signaling. B-Raf interacting proteins were identified by anti-HA-B-Raf IPs of cells treated with sorafenib compared to vector control 
cells (n=2; p<0.05). Bottom: B-RafD594A interacting proteins were identified by anti-HA-B-RafD594A IPs compared to B-RafWT IPs (n=2; 
p<0.05). Proteins were colored according to their log2 SILAC ratios. Networks were generated with STRING DB. C. Confirmation 
of the increase of Raf-1/B-Raf complexes immunoprecipitated with anti-HA antibody 3F10 matrix from MEFs upon H-RasG12V::ERTM 
release observed by SILAC-based MS by Western blotting. Note that due to its paradoxical behavior B-RafD594A recruits more Raf-1 
than B-RafWT as it also illustrated in B. D. B-Raf interacts with Kidins220/Arms in the presence of sorafenib. Braf deficient MEFs 
were infected with the indicated B-Raf expression constructs or the empty vector control and treated with 10 μM sorafenib or vehicle 
(DMSO). HA-tagged B-Raf complexes were immunoprecipitated and probed with an anti-Kidins220 antibody.
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New insights into B-Raf phosphorylation and 
ubiquitination
Next, we used our experimental systems to identify 
ubiquitination and phosphorylation sites on B-Raf. To 
this end, we applied a multi-protease approach [52], 
which has not been applied to B-Raf complexes so far 
and delivered a very good sequence coverage. In case of 
phospho-peptide analyses, we used TiO2-based enrichment 
protocols. In addition to K88 as novel ubiquitination 
site (Supplementary Table S5), we identified in total 36 
phosphorylation sites of which 10 have not been listed in 
the Phosphosite database (http://www.phosphosite.org/
proteinAction.action?id=577&showAllSites=true) and 
only eight have been subject to functional characterization 
so far (Supplementary Tables S6–S9). Importantly, several 
phosphorylation sites were observed in the three cell lines 
from chicken, mouse and man, indicating a conserved 
function in B-Raf regulation. As noted for other phospho-
proteins [53-55], most phosphorylation sites were located 
outside of the three structured domains, the RBD, CRD 
and kinase domain, and clustered in the BSR, the HR 
between CR2 and CR3, and the C-terminus (Figure 4A). 
This suggests that these areas reside in less-ordered states 
allowing easy access for kinases and phosphatases. Using 
bioinformatic tools like KinomeXplorer, Scansite or 
PhosphoNET, we list which kinases could be implicated in 
these phosphorylation events (Supplementary Table S6).
Several B-Raf phosphorylation sites are mutated 
in cancer
By combining the information obtained from our 
MS experiments and sequencing of tumor genomes, 
it is becoming increasingly obvious that somatic 
mutations identified in human cancers often affect 
phosphorylation sites [56, 57]. This can occur either 
directly or indirectly by altering surrounding residues 
constituting the motif mediating the kinase/substrate 
interaction or the phosphorylation-dependent recruitment 
of critical effectors such as 14-3-3 proteins. As shown 
in Supplementary Table S6, eleven and eight of the 
phosphorylation sites are directly or indirectly affected 
by mutations listed in the Catalogue of Somatic Mutation 
in Cancer (COSMIC; http://cancer.sanger.ac.uk/cosmic/
gene/overview?ln=BRAF), respectively. As a proof-of-
principle, we noticed that the 14-3-3 binding site S365 
and the adjacent S364 are replaced by leucine residues 
in tumor samples. Furthermore, P367, which represents 
an integral part of the 14-3-3 binding motif surrounding 
S365 (RXXpS365XP367; [58]), is substituted by arginine or 
serine residues. Loss of 14-3-3 binding to the CR2 due to 
mutation of S365 has been shown by various groups to 
increase the signaling potential of B-Raf and could thus 
contribute to tumorigenesis [13, 20, 25, 27]. At present, 
it is unclear whether phosphorylation of the conserved 
S364 is critical for B-Raf regulation or whether its leucine 
substitution might interfere with phosphorylation of S365 
and/or 14-3-3 binding. In any case, the cancer-associated 
mutations of the 14-3-3 binding motif surrounding S365 
represent an interesting parallel to the Noonan-Syndrome 
associated RAF1 mutations, affecting the equivalent motif 
around S259 in Raf-1 [59], and the cancer-associated 
mutations in the CR2 of A-Raf [60-62].
We addressed the function of several phosphorylation 
sites using various genetic and biochemical approaches 
such as B-Raf mutants in which the residues in question 
are replaced with either non-phosphorylatable or phospho-
mimetic residues. The first residue we re-addressed was 
S151, a phosphosite that has been recurrently identified 
in MS experiments (see http://www.phosphosite.
org/siteAction.do?id=74357), but whose function is 
controversially described in the literature. In agreement with 
two other studies using mammalian cells [26, 63], we show 
in our chicken DT40 complementation system (Figure 1A) 
that the S151A substitution does not abrogate B-Raf activity 
(Figure 4B). This was not necessarily expected as a study in 
Xenopus oocytes suggests that phosphorylation of the S151 
equivalent is required for activity of Xenopus B-Raf (XeB-
Raf; [64]). In fact, S151A, but not S151E, rather confers 
a slight increase in MEK/ERK phosphorylation upon 
EGF stimulation in B-Raf deficient DT40 cells in which 
we inducibly expressed these B-Raf proteins to a similar 
level as endogenous B-Raf (Figure 4C and Supplementary 
Figure S1A/S1B). To further assess the biological activity 
of S151 mutants, we expressed them in PC12 cells, a model 
system in which B-Raf gain-of-function mutants lower the 
threshold for spontaneous neuronal differentiation under 
normal growth conditions or in the presence of otherwise 
mitogenic growth factors like EGF [22, 27, 30]. Indeed, 
expression of B-RafS151A in PC12 cells induced a higher 
degree of spontaneous neuronal differentiation in the 
absence and presence of exogenous EGF, while B-RafS151E 
behaved similarly to B-RafWT (Figure 4D). However, the 
neuritogenic potential of B-RafS151A did not reach that of 
the more active B-RafS365A and B-RafV600E mutants. Based 
on pulldown experiments using GST-RasV12 as a bait and 
B-RafWT or B-RafS151A as a prey, S151, which is located at 
the N-terminal border of the RBD, has been implicated in 
controlling the Ras/B-Raf interaction [26, 63]. However, 
by performing alpha screen assays we could not detect 
statistically significant differences in Ras-binding affinity 
between the B-RafWT, B-RafS151A and B-RafS151E, although 
we noticed a trend for a reduced Ras interaction of 
the latter mutant that has not been investigated before 
(Supplementary Figure S1C). Similarly, we did not detect 
an obvious impact of S151 mutations on B-Raf homo-
dimerization (Supplementary Figure S1D).
The presented data and work by the Morrison 
group [26] indicate that phosphorylation of S151 by 
a proline-directed kinase, or a negative charge at this 
position, impairs the signaling potential of B-Raf. This 
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Figure 4: The B-Raf phospho-map and characterization of S151. A. The B-Raf phospho-map based on phosphorylation sites identified 
in this study (see Supplementary Table S6 for additional information).Shown is a representation of the B-Raf primary structure indicating CR1-3. 
B. Rescue of BCR-mediated ERK activation in Raf-1/B-Raf double deficient DT40 cells through add-back of B-RafWT and B-RafS151A. Parental 
DK37- cells, Raf-1/B-Raf deficient DK37+ cells and cells stable transfected either with chicken B-RafWT or B-RafS151A expression constructs (see 
Figure 1A) were stimulated with the anti-IgM antibody M4 for 5 min. TCLs were analyzed with the indicated antibodies. Successful stimulation of 
the cells was verified through detection of tyrosine-phosphorylated proteins (pY). C. pMEK/pERK levels are higher in BCR-stimulated DT40 cells 
re-expressing B-RafS151A compared to B-Rafwt and B-RafS151E. The inducible system is described in Supplementary Figure S1A/S1B. D. B-RafS151A 
displays a stronger neuritogenic potential than B-RafWT. PC12 cells transfected with the indicated pMIG/HAhB-Raf plasmids were identified by 
GFP fluorescence. The graph indicates the proportion of GFP-positive, differentiated cells relative to the total number of GFP-positive cells (n=3-
5, S.E.M.). Asterisks or + signs indicate an ANOVA single factor result between the HAhB-RafWT or the HAhB-RafS151A expressing cells and the 
indicated transfectants, respectively (* p < 0.02, ** p < 0.0001, + p < 0.02 and ++ p < 0.005). Upper and lower graph: cells grown in the absence 
or presence of 100 ng/ml EGF. E. and F. Phosphorylation of B-Raf at S151 is not affected by UO126. E. Endogenous B-Raf was purified from 
PC12 cells pre-treated with either DMSO (vehicle) or 20 µM UO126 for 2 h. F. B-Raf deprived DT40 cells re-expressing HA-tagged chicken 
B-Raf were pre-treated with either DMSO (vehicle) or 10 µM UO126 for 30 min and then stimulated with anti-IgM antibody M4. B-Raf was 
immunoprecipitated using anti-B-Raf H-145 antibodies and probed for phosphorylation at S151. Detection of pERK indicates successful MEK 
inhibition. Successful BCR stimulation is confirmed by the induction of tyrosine-phosphorylated bands typical for anti-IgM treated DT40 cells.
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concept is further supported by an entry in the COSMIC 
database listing a BRAFP152S mutation (Supplementary 
Table S6). This alteration destroys the consensus motif 
required for S151 phosphorylation by proline-directed 
kinases of the ERK and CDK subfamilies [65]. These 
findings raise the question which kinases control S151 
phosphorylation. Using metabolic labelling with 32P, the 
Morrison laboratory showed that growth factors induce 
the phosphorylation of S151 by a process that is sensitive 
to the MEK inhibitor UO126 [26, 66]. Similarly, UO126 
and PD98059, another MEK inhibitor, blocked S151 
phosphorylation in melanoma cells [63]. This implies 
that ERK itself phosphorylates S151. Interestingly, 
however, our MS analyses show that this site is already 
phosphorylated in unstimulated PC12 and DT40 cells. 
Furthermore, we observed in Western blot analyses using 
an anti-phospho-S151 antibody that UO126, despite 
strongly suppressing ERK phosphorylation, did not 
yield a discernible effect on S151 phosphorylation. This 
was observed for endogenous B-Raf in PC12 and in the 
B-Raf/Raf-1 proficient DT40 subline DK37- (Figure 
4E/4F). Thus, the half-life and mechanisms of S151 
phosphorylation might be more versatile and cell-type-
specific than previously thought and might even involve 
other kinases in addition to ERK. As XeB-Raf can be 
phosphorylated by CDKs [64] and as S151 is embedded in 
a CDK consensus phosphorylation motif (Supplementary 
Figure S1E), it might be possible that CDKs contribute 
to S151 phosphorylation. This remains an area for future 
studies.
Next, we focused on S465, which is located in the 
glycine-rich or P-loop and has been recently reported as 
an auto-phosphorylation site [67], although the functional 
characterization of this residue was here restricted to in 
vitro kinase assays. The P-loop represents the second 
hotspot for oncogenic mutations, such as G469A [68], or 
RASopathy mutations such as S467A [69]. Interestingly, 
a S465F substitution has been also reported for colorectal 
and lung cancer [70, 71]. It is tempting to speculate 
that phosphorylation of S465 interferes either with the 
auto-inhibition imposed by the hydrophobic interaction 
between P- and activation loop [68], or MEK binding 
[72]. We now extend the in vitro findings by Holderfield 
et al. [67] by showing that Braf−/− MEFs reconstituted 
with B-RafS465A display comparable pMEK/pERK levels 
than B-RafWT, either in the absence or presence of 
H-RasG12V::ERTM release (Figure 5A). Interestingly, the 
two phospho-mimetic mutants, B-RafS465D and B-RafS465E, 
behaved differently in this system. MEFs reconstituted 
with B-RafS465D presented a similar degree of MEK/ERK 
phosphorylation like B-RafWT and B-RafS465A expressing 
cells. Likewise, all three B-Raf proteins displayed 
similar electrophoretic mobility shifts (EMS) upon 
H-RasG12V::ERTM release indicating a similar pattern of 
PTMs. In contrast, MEFs expressing B-RafS465E showed 
lower pMEK/pERK levels compared to B-RafWT and 
B-RafS465A/D expressing cells and only a small and very 
discrete EMS upon H-RasG12V::ERTM release. This suggests 
that the glutamate substitution of S465 impairs the 
signaling potential of B-Raf and its activation dependent 
PTMs contributing to a maximum EMS. The strong 
negative charge introduced by the glutamate residue (or 
phosphate group) could either impair ATP coordination or 
block recognition of B-Raf by the HSP90 co-chaperone 
Cdc37, which binds to Raf kinases via its consensus motif 
GS465GSFG [73]. Both mechanisms would explain the loss 
of B-Raf activity.
Another site that was phosphorylated in B-Raf 
complexes from all three cell lines was S605, located in 
the activation loop. This evolutionary conserved residue is 
closely located to the T599VKS602-motif and is required for 
maximum B-Raf activity [22, 24], suggesting a potential 
role in Raf regulation. Furthermore, substitutions of S605 
by other residues are listed in the Catalogue of Somatic 
Mutations in Cancer (COSMIC; http://www.cancer.
sanger.ac.uk/cancergenome/projects/cosmic/), albeit at 
very low frequency compared to other activation segment 
mutations such as V600E/K. In order to analyze the 
role of this phosphorylation site and the so far unknown 
relevance of its mutation for the signaling potential of 
B-Raf, we replaced S605 by an alanine residue to prevent 
phosphorylation, by a phospho-mimetic glutamate 
residue or by a glycine residue, as the latter substitution 
represents the most frequently observed S605 alteration 
in the COSMIC database. Surprisingly, however, these 
substitutions had little to no effect on basal or oncogenic 
H-Ras stimulated B-Raf activation (Figure 5B). In fact, 
these S605 substitutions rather slightly reduced the 
MEK phosphorylation potential of these B-Raf mutants 
upon H-RasG12V::ERTM release. Furthermore, they did not 
induce paradoxical MEK/ERK phosphorylation, as it has 
been described for inhibitor-bound B-Raf or kinase-dead 
mutants such as B-RafD594A in this context [13], or show 
any cooperativity with oncogenic Ras, as we have recently 
shown for the intermediate activity B-RafF595L mutant [74]. 
Thus, phosphorylation of S605, at least by itself, and the 
cancer-associated S605G mutation are neither playing a 
pivotal role in B-Raf activity nor as an oncogenic driver, 
respectively.
Dynamic phosphorylation events in the hinge 
region of B-Raf
We also applied SILAC-based MS to obtain 
quantitative insights into the dynamics of B-Raf 
phosphorylation under certain conditions. For example, 
B-Raf, rendered catalytically inactive by either the D594A 
mutation or by binding to various ATP-competing Raf-
inhibitors such as sorafenib, experiences a pronounced 
EMS in cells expressing oncogenic Ras (Figure 6A) [13, 
16]. To identify the phosphorylation events associated with 
B-Raf inhibition, we complemented Braf deficient MEFs 
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Figure 5: Functional characterization of the phosphorylation sites S465 and S605 in oncogenic Ras signaling. Braf−/− 
MEFS expressing the ERTmH-RASG12V fusion protein were infected and treated with the indicated B-Raf expression vectors as described 
in Figure 1B/1C. TCLs were analyzed using the indicated antibodies. A. Analysis of the P-loop phosphorylation site S465. B. Analysis of 
the activation loop phosphorylation site S605.
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Figure 6: The HR of B-Raf contains two conserved and isoform-specific phosphorylation clusters contributing to 
the prominent EMS observed under conditions of B-Raf inhibition/inactivity. A. Oncogenic Ras induces a marked EMS of 
B-RafD594A (left) or B-RafWT (right) in sorafenib-treated MEFs. B. Plot showing the relative abundance of the mono-phosphorylated and 
tetra-phosphorylated peptide encompassing T401 in B-Raf purifications from MEFs expressing B-RafWT (light medium) and B-RafD594A 
(heavy medium). The peptide RGDGGSTTGLSAPTPPASLPGSLTNVKAL (pos. 389-416) was identified as mono- (upper panel), di-, tri- 
and tetra- (lower panel) phosphorylated. Position 401 was identified as phosphorylated in all versions of the peptide. Additional sites could 
not be unambiguously localized and are marked in red. Note the abundance of tetra-phosphorylated peptides in peptide preparations from 
the B-RafD594A mutant compared to those from B-RafWT. C. Position and sequence of the HR peptides differentially phosphorylated upon 
kinase inhibition or inactivity. The putative initial phosphorylation sites T401 and S419 are indicated by red letters. D. Alignment of the 
hinge region located between the CR2 and the CR3 as defined by [110]. Asterisks indicate confirmed or potential phospho-acceptor sites 
replaced by alanine residues in the T401 and S419 cluster mutants. E. ClustalW2 based alignment of three human Raf-paralogues: A-Raf 
(NP_001243125), B-Raf (P15056.4) and Raf-1 (P04049.1)). Sites at an equivalent position to the HR phosphorylation sites identified in 
B-Raf are highlighted in blue. Asterisks indicate phosphorylation sites previously identified in Raf-1 [77] and A-Raf [75].
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with either B-RafWT or catalytically inactive B-RafD594A 
and compared the relative abundances of B-Raf derived 
phospho-peptides. This analysis revealed a significant 
increase of phospho-peptides encompassing T401 and 
S419 in B-RafD594A preparations compared to those from 
B-RafWT. Importantly, this analysis demonstrated that, in 
addition to the previously identified T401, S419 and S429 
sites [26], the hinge region of B-Raf (HR) was additionally 
phosphorylated at multiple residues, thereby representing 
previously unrecognized phosphorylation clusters (Figure 
6B/6C and Supplementary Tables S6 and S9). Likewise, 
sorafenib treatment induced an increase in the abundance 
of tetra-phosphorylated peptides encompassing T401 
(Supplementary Tables S6 and S9). In both cases, single 
phosphorylated peptides containing either T401 or S419 
could be identified in IPs from control cells, suggesting 
that these residues are probably “priming” sites that are 
also phosphorylated under basal conditions. Therefore, 
we will refer to these areas in the HR as the T401 and 
S419 cluster in the following. Although it is sometimes 
difficult to pinpoint the exact phosphorylation site in a 
multi-phosphorylated peptide, it seems that, in case of the 
latter peptide, S419 is already phosphorylated in B-RafWT, 
while the C-terminally located serine cluster becomes 
completely phosphorylated in B-RafD594A. In case of the 
peptide encompassing T401, it is more difficult to allocate 
the sites in addition to phospho-T401. Based on the mass 
spectra, however, it is obvious that additional residues 
located N- and C-terminal of T401 become phosphorylated 
in B-RafD594A or B-RafWT purified from sorafenib treated 
cells. Interestingly, T401 and the N-terminally located 
phosphorylation sites were also phosphorylated in 
membrane-tethered and hence activated B-RafCAAX 
(Supplementary Tables S6 and S8). A protein sequence 
alignment revealed that the phosphorylation sites in these 
residues are highly conserved during vertebrate evolution 
(Figure 6D). The multi-phosphorylation of the T401 and 
S419 encompassing peptides is of particular interest in 
the light of the isoform-specific regulation and function 
of Raf-kinases. Indeed, as already pointed out previously 
[75], the three mammalian Raf-isoforms display 
considerable differences in their amino acid sequences in 
the HR between CR2 and CR3 and consequently in terms 
of their potential phosphorylation sites and motifs (Figure 
6E). Interestingly, work by the Rapp and Morrison groups, 
which have mapped and functionally characterized these 
phosphorylation sites in A-Raf and Raf-1, suggests that 
they are regulated and contribute to Raf signaling in an 
isoform-specific manner [75-77]. Indeed, the majority of 
phosphorylation sites in A-Raf and Raf-1 represent bona 
fide phosphorylation sites for proline-directed kinases such 
as ERK, as it was also confirmed experimentally [75, 77, 
78]. In contrast, all the sites in the hinge region clusters 
in B-Raf, except for T401 and S419 themselves, do not 
conform to phosphorylation motifs of proline-directed 
kinases [79].
The hinge region phosphorylation events 
strongly contribute to the EMS of B-Raf
Next, we asked how these phosphorylation site 
clusters contribute to the pronounced EMS of B-RafD594A 
or B-RafWT in sorafenib treated cells with active Ras 
signaling. Therefore, we replaced all phosphorylation 
sites in the T401 or the S419 cluster (Figure 6D) by 
alanine residues and expressed these mutants in the Braf−/− 
MEF complementation system (Figure 7A). Alanine 
substitutions of the phosphorylation sites in the T401 
cluster strongly reduced the pronounced EMS of B-RafD594A 
in total cellular lysates (TCLs) and immunoprecipitates. In 
contrast, alanine substitutions of the phosphorylation sites 
in the S419 cluster affected the EMS of B-RafD594A to a 
lesser but discernible extent. Similar findings were made 
for both clusters in the B-RafWT background in sorafenib 
treated MEFs with activated Ras signaling (Figure 7B). 
These analyses revealed that MEFs complemented 
with a B-RafWT protein lacking the phospho-acceptor 
sites of the T401 cluster displayed slightly elevated 
pMEK and pERK levels under basal conditions (Figure 
7A/7B). Furthermore, using an antibody recognizing 
phosphorylated T401, we show that this residue was 
already phosphorylated in MEFs in the absence of 4-HT 
and that induction of oncogenic Ras signaling did not lead 
to an increase in T401 phosphorylation. This observation 
is in agreement with our SILAC-based MS results.
Phosphorylation of the T401 cluster is 
vemurafenib sensitive
Having shown that the HR phosphorylation 
clusters are strong contributors to the EMS of B-Raf 
observed in sorafenib treated cells or in the context of the 
D594A mutation, we next asked which kinase(s) could 
phosphorylate these clusters. As we previously observed 
in in vitro kinase (IVK) assays involving B-RafV600E that 
this hyperactive oncoprotein also undergoes a pronounced 
EMS, which is reminiscent to that displayed by B-RafD594A 
in cells with active Ras signaling, we reasoned that the HR 
clusters could be targeted by an auto-phosphorylation in 
cis or in trans (Ref. 13 and Figure 8A). This assumption 
was further supported by the observation that this EMS 
was dependent on the presence of ATP in the IVK reaction 
and required an intact DIF, suggesting that the associated 
phosphorylation events are mediated in trans in B-RafV600E 
homo- or heterodimers [13]. To further test the hypothesis 
that the HR is subject to such auto-phosphorylation 
events, we expressed a B-RafV600E protein with alanine 
substitutions of HR phosphorylation sites in Plat-E cells 
(Figure 8A). Plat-E cells, a HEK293 derivative, were 
chosen as they are highly suitable assays for transient 
transfection assays as a basis for IVK [13]. Indeed, alanine 
substitutions of the T401 but not of the S419 cluster 
significantly affected the EMS of B-RafV600E in IVK assays 
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Figure 7: The HR phosphorylation clusters contribute to the EMS associated with B-Raf inhibition or inactivity. Braf−/− 
MEFs expressing the ERTmH-RASG12V fusion protein were infected and treated with the indicated B-Raf expression vectors as described 
in Figure 1B/1C. TCLs and IPs were analyzed using the indicated antibodies. A. Analysis of the HR phosphorylation clusters in the context 
of the wildtype protein and the kinase-inactivating D594A mutation. B. Analysis of the HR phosphorylation clusters in the context of the 
hyper-phosphorylation displayed by B-RafWT in the context of sorafenib and oncogenic Ras signaling. Note that the Ras-induced shift of 
B-RafWT is further enhanced by the addition of sorafenib.
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Figure 8: Phosphorylation of the T401 cluster is vemurafenib (PLX4032) sensitive. A. Plat-E cells were transfected with the 
indicated B-Raf expression vectors. B-Raf signaling was analyzed by an in vitro kinase (IVK) assay and in TCLs. Note that mutation of the 
T401 cluster reduces the EMS of B-RafV600E in the IVK but also in the TCL despite not having an effect on its high MEK phosphorylation 
potential. B. IVK assay as performed in (A) except that PLX4032 was added to the bead suspension prior to addition of ATP.
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and also in TCLs. Importantly, as mutation of neither the 
T401 nor the S419 cluster had a significant effect on the 
IVK activity or the MEK/ERK phosphorylation potential 
of B-RafV600E in cells (Figure 8A), we can rule out that 
these alterations block the enzymatic activity of the 
oncoprotein. To further demonstrate that the maximum 
EMS of B-RafV600E is driven by phosphorylation of the 
T401 cluster, we added vemurafenib (PLX 4032) to the 
IVK reaction prior to the addition of ATP (Figure 8B). 
This inhibitor accelerated the electrophoretic mobility 
of B-RafV600E but not of B-RafV600E/T529N, a gatekeeper 
mutant resistant towards various Raf inhibitors [80]. 
This indicates that the kinase activity of B-RafV600E is 
essential for this shift. The migration of B-RafV600E/T529N 
as a doublet could be explained by the fact that this 
gatekeeper mutation also reduces its IVK activity [81]. 
Consequently, some B-Raf molecules are probably not 
completely phosphorylated and therefore migrate faster in 
the gel. Importantly, B-RafV600E/T529N/T401cluster migrates faster 
than the B-RafV600E/T529N mutant, further demonstrating that 
the phosphorylated T401 cluster contributes to the IVK 
EMS (Figure 8B). Taken together, these observations 
confirm that phosphorylation of the T401 cluster can be 
achieved in vitro and that this cluster contributes to the 
phosphorylation status of B-RafV600E in cells prior to lysis. 
As we will further discuss below, the DIF dependency, as 
demonstrated by the effect of the R509H mutation, and 
vemurafenib sensitivity of this process suggest an auto-
phosphorylation in trans.
Loss of the T401 phosphorylation cluster 
enhances cellular transformation
As conservation of the T401 cluster during 
vertebrate evolution suggests an important function, we 
next addressed its biological relevance. As mutation of 
both clusters had no discernible impact on the MEK/ERK 
phosphorylation potential of the highly active B-RafV600E 
oncoprotein (Figure 8A), we decided to address their 
role in the background of B-RafWT, either under basal 
conditions or in the presence of oncogenic Ras. However, 
the combination of re-expressing B-Raf, in particular 
B-RafD594A, with oncogenic Ras strongly reduced cellular 
adhesion over the time course of two weeks that was 
necessary for focus formation. Consequently, no stable 
foci were formed. Therefore, we sought to test the HR 
mutants in a cellular system with elevated activity of 
endogenous Ras. To this end, we used MEFs with a 
doxycycline inducible knockdown of neurofibromatosis 
1 (NF1), a potent negative regulator of Ras proteins 
and tumor suppressor gene product [82, 83] (Figure 
9A). Depletion of NF1 results in increased levels of 
GTP-loaded Ras isoforms and consequently increases 
downstream signaling [83]. However, the effects of NF1 
depletion on pMEK/pERK levels and immediate early 
gene products such as DUSP6 were rather subtle and could 
be explained by the dynamic counter-regulation of ERK 
pathway activity by multiple transcriptional and post-
translational feedback loops acting at various levels of this 
pathway [78, 84-86]. Therefore, as a biological endpoint 
integrating mitogenic signaling events over a period of 
14 days, we studied focus formation of MEFs transduced 
with the various B-Raf mutants (Figure 9C/9D). In cells 
transduced with non-silencing control shRNA, expression 
of B-RafWT moderately increased the number and diameter 
of transformed foci compared to MEFs infected with 
the empty vector control construct, while expression 
of B-RafWT and NF1 knockdown cooperated in a more 
efficient focus formation. Focus formation was even more 
pronounced in MEFs transduced with B-RafT401cluster and, 
as expected from the well-established cooperation of 
kinase-inactive B-Raf mutants with active Ras [16], also 
in cells expressing B-RafD594A proteins. Commensurate 
with its lack of an effect on MEK/ERK phosphorylation 
(compared to B-RafWT expressing MEFs), alanine 
substitution of the phosphorylation sites in the S419 
cluster had no discernible impact on the transformation 
potential of B-RafWT. In summary, our data suggest that 
the hyper-phosphorylation of the T401 cluster represents 
a negative signaling event limiting the activation of 
B-RafWT.
DISCUSSION
Using a proteomic approach, we obtained detailed 
new insights into the interaction repertoire of B-Raf and 
the spectrum of its phosphorylation sites. In respect to 
the former, we could identify a series of novel interaction 
partners and now also supply information regarding the 
dynamics of their recruitment. For example, our SILAC 
experiments have shown that the interaction of B-RafD594A 
with Ras-isoforms (or the H-RasG12V::ERTM fusion protein 
as reflected by the enrichment of estrogen receptor derived 
peptides) or Raf-1 or A-Raf is strongly enhanced by 4-HT 
treatment. These findings validate our approach and 
the identification of novel or less-established dynamic 
interaction partners such as Kidins220/ARMS (Figure 3D) 
or ECM29. Unfortunately, we were not able to confirm the 
latter by Western blot analysis due to the lack of suitable 
antibodies.
Amongst the novel interaction partners of B-Raf, the 
a subunits of hetero-trimeric G-proteins are of particular 
interest for two reasons. Firstly, this interaction could 
represent a “missing link” in the crosstalk between 
RTKs and G protein-coupled receptor (GPCR) signaling 
systems. Indeed, while trans-activation of RTKs by 
GPCRs is a relatively well-established phenomenon [87, 
88], other studies proposed that RTKs could also signal via 
GPCRs or “hijack” their cytoplasmic signal transducers 
such as hetero-dimeric G-proteins [89]. Secondly, mutated 
Gα subunits are emerging as potent oncoproteins in 
human cancer. For example, mutations likely to impair 
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Figure 9: The B-RafT401cluster suppresses the transforming potential of B-RafWT. MEFs were infected with a lentiviral vector 
allowing the doxycycline (dox) inducible expression of either Nf1-specific or non-silencing control shRNA. MEFs were then infected with 
retroviral vectors encoding the indicated B-Raf proteins and then exposed to dox. A. Western Blot demonstrating NF1 depletion after five 
days of Dox treatment. B. Western blot analysis of the MEK/ERK pathway five days after dox addition. Samples were run on the same gel 
in non-contiguous set-up and intervening lanes were cropped out. C. MEFs transduced with dox inducible expression cassettes for either 
a non-silencing control or NF1 specific shRNA were transduced with the indicated B-Raf expression vectors, grown in the presence of 
dox and stained with Giemsa to reveal foci after 14 days. D. Bar graph showing number of colonies from three independent infections. 
Colony numbers in MEFs infected with the pTRIPZ non-silencing construct and pMIG/HA-BRAFWT were arbitrarily set in each individual 
infection to 1. Asterisks indicate relevant statistically significant effects (2-way ANOVA; uncorrected Fisher’s LSD test); ** p<0.001; 
*p<0.05. Further statistics are provided in Supplementary Table S10.
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GTP hydrolysis have been identified in the Gα subunits 
genes GNAS, GNAI2 and GNAO1 [90, 91]. Furthermore, 
GNAQ and GNA11 mutations blocking GTP hydrolysis 
were identified in melanocytic neoplasms such as uveal 
melanoma and blue nevi [92, 93]. Importantly, uveal 
melanoma shares with cutaneous melanoma the addiction 
to high levels of ERK activity, but lack NRAS or BRAF 
mutations that are a hallmark of cutaneous melanoma [92]. 
However, the immediate critical effectors downstream 
of mutated Gα subunits are still unknown and currently 
a more indirect activation of the ERK pathway via Gα 
subunit mediated activation of phospholipase C/Ras and 
protein kinase C isoforms is discussed in the field [94-96]. 
Although our data do not rule out an involvement of these 
enzymes, our discovery that B-Raf signalosomes purified 
from three distinct cell types contain Gα subunits suggests 
a more direct link between heterotrimeric G-proteins 
and the ERK pathway module. This scenario is further 
supported by our finding that deamidation of Gα subunits 
by PMT, and thereby preserving their GTP loaded state, 
increases their interaction with B-Raf.
In addition to the multiple and dynamic protein-
protein interactions, the high number of phosphorylation 
sites as well as the emerging ubiquitination (this study, [97, 
98], acetylation (Phosphosite database) and methylation 
events [99] further demonstrate the role of B-Raf as a 
signaling hub integrating multiple signaling pathways. In 
this study, we have focused on establishing a catalog of 
phosphorylation sites identified on B-Raf proteins purified 
from various cell types and conditions. In addition to 
well-established phosphorylation sites linked to B-Raf 
activation (S446; [100]), 14-3-3 binding (S365/S729; [25, 
27, 28]) and feedback regulation (S751/T753; [29, 30]), 
we have confirmed and further characterized more recently 
identified sites such as S151 and discovered several novel 
ones. Indeed, SILAC-based MS analyses enabled us 
to identify two dynamically regulated phosphorylation 
clusters located in the HR of B-Raf, which are both mainly 
responsible for a long-standing phenomenon in B-Raf 
research, the dramatic and dimerization-dependent EMS 
of B-RafV600E, of kinase-dead B-RafD594A or drug-bound 
B-RafWT (with the latter two in the context of oncogenic 
Ras signaling; [13, 16]). This HR promoted “super-shift” 
is distinct from the typical shift of Raf-kinases that is 
triggered by growth factor or antigen receptors, or by 
expression of oncogenic Ras and that is driven by their 
ERK mediated feedback phosphorylation [26, 29, 48, 78]. 
Instead, by using B-RafV600E mutants rendered resistant 
towards the B-Raf inhibitor vemurafenib, we demonstrate 
that the T401 cluster in the HR is phosphorylated by a 
mechanism involving their own kinase activity. At first 
glance, these findings contradict our observation that 
the T401 cluster is hyper-phosphorylated in complexes 
purified from MEFs that either have been complemented 
with B-RafWT and treated with sorafenib, or that express 
kinase-dead B-RafD594A. In both settings, one would expect 
any auto-phosphorylation to be disabled. However, we 
have shown previously that the R509H mutation impairs 
the “super-shift” of B-RafV600E (in vitro and in vivo), 
of B-RafD594A and even that of B-RafWT in the presence 
of oncogenic Ras and sorafenib [13]. This suggests 
that HR phosphorylation occurs in trans and could be 
even mediated by another Raf-isoform such as Raf-
1 or A-Raf that are both highly enriched in B-RafD594A 
complexes and should be strongly activated due to 
the paradoxical action of kinase-dead B-Raf [13, 16]. 
This model is supported by our recent study showing 
that a B-RafD594A mutant (B-RafD594A/AVKA) with alanine 
substitutions of the activation loop phosphorylation sites 
T599 and S602 exhibits an impaired EMS in the context 
of H-RasG12V::ERTM release and recruits significantly less 
Raf-1 than B-RafD594A proper [24]. As the differential 
between the EMS of B-RafD594A and B-RafD594A/AVKA is 
reminiscent of that between B-RafD594A and B-RafD594A/
T401cluster, it is tempting to speculate that the contrasting 
EMS of B-RafD594A and B-RafD594A/AVKA are caused by 
the less efficacious recruitment and transactivation of 
Raf-1 (see Ref. [24] for further discussion). Likewise, as 
the application of 10 μM sorafenib does not completely 
eradicate MEK/ERK phosphorylation and also strongly 
stabilizes B-Raf/Raf-1 complexes ([13, 16]; Figure 2B), 
one might speculate that dimers in which one B-Raf is 
drug-bound, and hence a potent allosteric activator, 
mediates hyper-activation of a drug-free protomer that 
in turn phosphorylates the HR in the activating protomer 
in trans. Furthermore, as we and others have shown 
that B-RafV600E exhibits an increased homo-dimerization 
potential relative to B-RafWT [13, 23], it is conceivable that 
the super-shift displayed by this oncoprotein in IVK assays 
is strongly promoted by trans-phosphorylation of the HR 
in the precipitated dimer and the presence of phosphatase 
inhibitors in this setting. The identification of these auto-/
transphosphorylation events invites for the identification 
of Raf consensus phosphorylation sites.
But what is the biological meaning of HR 
phosphorylation? While the precise role of the S419 
cluster, which precedes one of the three established 
inhibitory AKT phosphorylation site S429 [101], remains 
to be characterized, we could show that mutation of the 
T401 cluster enhances the transformation potential of 
B-RafWT. As the structure of the HR is unknown and 
is probably highly disordered, we can only speculate 
about the precise molecular mechanisms by which 
phosphorylation of the T401 cluster contributes to B-Raf 
downregulation. For example, it is conceivable that 
HR phosphorylation counteracts the attachment to the 
negatively charged inner leaflet of the plasma-membrane 
by bulk changes in the electrostatic landscape of this 
B-Raf region [102]. Such a scenario has been shown for 
the yeast MAPK scaffold Ste5, which harbors a cluster of 
CDK phosphorylation sites in its basic membrane binding 
region [103]. Alternatively, HR cluster phosphorylation 
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could contribute to loosen B-Raf homo- or heterodimers 
in a mechanism already suggested by the Kölch and 
Morrison laboratories for the phosphorylation of S151 and 
the C-terminal SPKTP-motif [26, 30, 66]. Interestingly, 
T401, as a single site and not as a member of a cluster, was 
also implicated in this process [26, 44, 66].
In summary, our data imply that following Ras-
mediated recruitment and dimerization, the HR becomes 
highly phosphorylated in trans thereby contributing to the 
downregulation of B-Raf activity or expression (Figure 
10). In regard to the latter possibility, it should be noted 
that the T401 equivalent in LIN-45 is part of a phospho-
degron promoting its degradation via the Skp1/Cul1/F-
box (SCF) complex [104]. As others and we observed 
previously that B-RafD594A expression often appears reduced 
in the presence of oncogenic Ras [13, 16], which is the 
setting in which T401 cluster phosphorylation occurs, it is 
tempting to speculate that HR phosphorylation contributes 
to the control of B-Raf turnover. This concept, which will 
be addressed in future studies, is further supported by the 
observation that B-Raf becomes ubiquitinated and interacts 
with Skp1 as well (this study; [98]). Indeed, while our 
manuscript was under revision, Hernandez et al. reported 
that alanine substitution of T401 and S405, a site that was 
also highlighted by the MASCOT software in our data sets 
but which was not included in Supplementary Table S6 due 
to its low score, increased the half-life of B-RafV600E [105]. 
Moreover, based on the dynamics of HR phosphorylation 
revealed by our SILAC approach, we posit that the HR 
cluster phosphorylation involves a kinetic proofreading 
mechanism in which only the processive integration of 
multiple phosphorylation sites can execute a decision such 
as the disruption of a protein-protein or –lipid interaction 
or tagging the protein for its degradation [106]. As we 
found T401 and S419 to be phosphorylated under normal 
growth conditions, we further postulate that these residues 
serve as pioneering or seeding sites that might predispose 
the clusters for maximum phosphorylation. Although this 
Figure 10: Model summarizing some key findings from the MS analyses of B-Raf complexes. Following recruitment by Ras 
and homo- or heterodimerization mediated transactivation, the Raf dimer becomes fully active following activation loop phosphorylation 
and DIF mediated allosteric activation (blue bent double-headed arrow). For simplicity, we show only the situation for B-Raf homo-dimers, 
but we posit a similar mechanism for heterodimers. Under normal activation, the B-Raf homo-or heterodimer is disrupted by feedback 
phosphorylation and the protomers are recycled to a closed inactive conformation by the action of Pin1 and various phosphatases such 
as Calcineurin, which dephosphorylates pT401 [44], or the other phosphatases that were identified in B-Raf complexes (Supplementary 
Table S1). If the activity of the dimer persists, the protomers will auto-phosphorylate themselves either in cis or trans at S465 in the kinase 
domain (orange) or at the HR indicated by the large phosphate group symbols N-terminal of the N-region (SSDD-motif). This hyper-
phosphorylation might then lead to dimer disassembly (in concert with the ERK mediated feedback phosphorylations) and/or degradation. 
See text for further details. Model has been extended from [24].
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concept needs to be addressed experimentally, the fact that 
both presumptive pioneering sites are somatically mutated 
in human cancer (Supplementary Table S6) and the fact that 
the T401A single mutant already elevates B-Raf signaling 
output ([44] and our own preliminary data) argue in this 
direction.
Finally, our study shows that B-Raf is a heavily 
phosphorylated protein. Although many of the sites 
identified or confirmed in broader settings by our study 
await their functional characterization, it is becoming 
clear that negative regulatory sites such as S151, S365, the 
T401 cluster, S429, S465 and the SPKTP-motif outnumber 
the few sites with a clear positive role such as S445, the 
T599VKS602-motif and S729. Thus, in line with its role 
as a potent proto-oncogene product, B-Raf is subject to 
multiple layers of negative regulation, allowing its fine-
tuning in a spatio-temporal manner. Our study further 
highlights the usefulness to combine phospho-proteomic 
with sequencing data of tumor genomes, as both data 
sets can complement each other in the elucidation of 
phosphorylation site function.
MATERIALS AND METHODS
Antibodies and reagents
Raf-B (F7, sc-5284), Raf-B (H145, sc-9002), Raf-
1 (C12, sc-133), β-actin (C4, sc-47778), α-Tubulin (B-
5-1-2, sc-23948), and NF1 (sc-67)were fromSanta Cruz 
Biotechnology; HA (3F10) monoclonal rat from Roche 
Bioscience.. Antibodies against (p)ERK, (p)MEK were 
purchased from Cell Signaling Technologies. The Gα 
switch antibody and the source of PMT were described 
recently [96]. DUSP6 was purchased from LsBio. 
Anti-Kidins220 antibody (ab34790) and GAPDH were 
purchased from abcam. Anti-phospho-tyrosine 4G10 
antibody was obtained from Upstate Biotechnology/ 
Millipore. Raf-B pT401 was from Epitomics. The anti-
pS151 antibody has been described previously [63].
Plasmids
The pFLU/HAchB-raf, pMIG/HAchB-raf, 
pAloxP-puro, pMIG/HAhBRAF and pMIG/BRAF-His/
Myc expression vectors were described previously [13, 
29, 107]. The pCDNA3.1loxPuro-HAchBRAF vector 
was a kind gift from Dr. Niklas Engels (Göttingen) and 
contains the HA-tagged chicken c-Rmil/B-Raf cDNA [29]. 
Mutations were introduced with standard site-directed 
mutagenesis. Oligonucleotide sequences and cloning 
strategies are available on request. To generate the dox-
inducible pTRIPZ-NF1 construct, parts of the shRNAmir 
cassette were isolated from pGIPZ V2LMM_194180 
(OpenBiosystems) and subcloned into pTRIPZ 
(OpenBiosystems). The sequence of the mature shRNA 
targeting NF1 is 5’-TAAATTTAAGGCTTGTTAC-3’.
Cell lines
The propagation of DT40, PC12, MCF-
10AecoR, Plat-E cells and Braf−/− MEFs expressing the 
H-RasG12V::ERTM fusion protein has been described [5, 
13, 29, 108]. For the MS analysis of endogenous B-Raf 
complexes, MEFs from BraffloxAVKA mice were used 
without previous Cre activation [24]. The generation 
and culture of immortalized MEFs from conditional 
Braf deficient mouse embryos (MEF#3 BraffloxE12/floxE12; 
pMIBerry/CreERT2) were described previously [13]. 
The DT40 subline allowing the 4-hydroxy-tamoxifen 
(4-HT) inducible deletion of the chicken c-mil/raf-1 
and c-Rmil/B-raf genes, DT40MCM/raf-1flE3/B-rafflE6 
(DT40floxRaf in short) has been described [5]. DK37+ cells 
were complemented with pMIG/HAchB-raf as described 
previously [5]. For inducible complementation analyses, 
DT40floxRaf cells (subclone DK37) were first converted to 
DT40Raf-less cells by 4-HT exposure for 24 h as described 
previously [5] and subsequently cultured in normal 
culture medium for additional four days. Subsequently, 
the cells were electroporated with 20 μg AhdI-linearised 
pCDNA3.1loxPuro-HAchBRAF and selected with 0.5 
μg/ml puromycine. PC12 cells were transfected by using 
Gene Juice (Novagen), kept in differentiation medium 
and scored for differentiation 6 days later as described 
previously [27, 29]. Cells were defined as differentiated if 
their neurites were longer than the size of two cell bodies. 
In order to generate MEFs with a conditional knockdown 
of NF1, SV40 Tag immortalized murine embryonic 
fibroblasts (MEF #3 FloxE12 pMIBerry/CreERT2; [13]) 
were infected with lentiviral particles containing either 
the pTRIPZ-non silencing (OpenBiosystems) or pTRIPZ-
NF1 construct as described previously [13]. MEFs were 
selected with 4 μg/ml puromycine (Carl Roth). Retro- and 
lentiviral infections, incl. focus formation assays, were 
performed as described previously [13, 24, 74].
Immunoprecipitation, in vitro kinase assays and 
western blotting
These procedures were conducted as described 
in detail previously [13]. In brief, cells were lysed in 
normal lysis buffer (NLB: 50 mM Tris/HCl, pH 7.5; 1% 
Triton X-100; 137 mM sodium chloride; 1% glycerin; 
1 mM sodium orthovanadate; 0.5 mM EDTA; 0.01 μg/
μl leupeptin, 0.1 μg/μl aprotinin, 1 mM AEBSF). Blotted 
proteins were visualized with horseradish peroxidase-
conjugated secondary antibodies (Roche) using the 
SuperSignal West Femto Maximum Sensitivity Substrate 
(Thermo Scientific) and either a LAS-4000 reader 
(FujiFilm) or a Fusion Solo chemiluminescence reader. 
Densitometry was performed using MultiGauge software 
(FujiFilm) or FusionCapt software (Vilber Lourmat). 
MS analysis of immunoprecipitated B-Raf complexes is 
described in detail in the expanded view.
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Ras/Raf interaction assays
HEK293T cells were co-transfected with pMIG/
HAhBRAF and V5-RasG12V expression vectors in a 2:1 
ratio as described previously [13]. Cells were harvested 
24 to 48 h post transfection with cell lysis buffer (50 
mM Tris-HCl pH 7.4, 1 % Triton-X100, 137.5 mM 
NaCl, 1 % glycerol, 1 mM sodium orthovanadate, 0.5 
mM EDTA pH 8, protease inhibitor cocktail (Roche)). 
Immunoprecipitations were performed as described 
previously [108]. AlphaScreen assays were performed 
in white 384-well OptiPlates using AlphaScreen Protein 
A Acceptor and Streptavidin Donor beads provided in 
a suspension of 5 mg/ml (all PerkinElmer). A detailed 
description of this assay is available upon request.
Mass spectrometry
Detailed information on mass spectrometry 
procedures is provided in the supplement. The mass 
spectrometry proteomics data have been deposited to 
the ProteomeXchange Consortium [109] via the PRIDE 
partner repository with the dataset identifier PXD003256.
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